Contrasting Pivotal Therapeutics (OTCMKTS:PVTTF) & Ardelyx (NASDAQ:ARDX)

Ardelyx (NASDAQ:ARDX) and Pivotal Therapeutics (OTCMKTS:PVTTF) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Valuation & Earnings

This table compares Ardelyx and Pivotal Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32 million	3.13	-$61.60 million	($0.23)	-22.43
Pivotal Therapeutics	N/A	N/A	N/A	N/A	N/A

Pivotal Therapeutics has lower revenue, but higher earnings than Ardelyx.

Analyst Ratings

This is a breakdown of current ratings for Ardelyx and Pivotal Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	1	0	9	1	2.91
Pivotal Therapeutics	0	0	0	0	0.00

Ardelyx currently has a consensus price target of $15.73, suggesting a potential upside of 204.79%. Given Ardelyx’s stronger consensus rating and higher possible upside, research analysts clearly believe Ardelyx is more favorable than Pivotal Therapeutics.

Profitability

This table compares Ardelyx and Pivotal Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ardelyx	-13.58%	-38.11%	-11.85%
Pivotal Therapeutics	N/A	N/A	N/A

Institutional & Insider Ownership

58.9% of Ardelyx shares are held by institutional investors. 5.3% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Ardelyx beats Pivotal Therapeutics on 7 of the 10 factors compared between the two stocks.

About Ardelyx

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

About Pivotal Therapeutics

Pivotal Therapeutics Inc., a specialty pharmaceutical company, focuses on the treatment of cardiovascular diseases and overall health. Its lead product, VASCAZEN, is a prescription only medical food formulated for clinical dietary management of cardiovascular disease in patients with documented coronary heart disease and who are deficient in blood Omega-3 fatty acids, eicosapentaenoic acid, and docosahexanenoic acid levels. The company also offers OMAZEN for the maintenance of good health through elevating Omega-3 fatty acid levels. In addition, the company develops Benefishial product line for overall health, cardiovascular health, prenatal health, toddler’s health, child’s health, and pet’s health. Further, it is developing PVT-100 indicated for the stabilization of vulnerable plaque in patients undergoing carotid endarterectomy. Pivotal Therapeutics Inc. sells VASCAZEN in the United States and OMAZEN in Canada. The company is headquartered in Woodbridge, Canada.